预测初次肿瘤细胞减灭术镜下残留病的模型:NRG肿瘤学/妇科肿瘤学组182研究
该研究利用GOG 182数据开发并验证预测晚期上皮性卵巢癌初次肿瘤细胞减灭术达到镜下无残留(R0)的模型。训练集1007例(234例R0),验证集473例(122例R0)。简化多变量模型含疾病评分、分期、CA125、腹水及分期-年龄交互项;验证集AUC为0.73(95%CI 0.67-0.78),加入疾病评分后AUC提升至0.83(95%CI 0.79-0.88)。
要点
- 模型预测R0的验证集AUC为0.73,加入疾病评分后提升至0.83。
- 预测变量包括疾病评分、分期、CA125、腹水和分期-年龄交互项。
- 作者认为未来需探索影像、分子分型等额外因素以提升临床实用性。
核心结论
- 开发并验证了预测R0的模型,性能优于既往报道的残留病预测模型。
- 模型性能提示未来应探索影像、分子分型等额外因素以形成更具临床可操作性的工具。
研究设计与样本
- 基于GOG 182记录收集人口学、病理、手术和CA125数据。
- 2003年9月1日前入组患者用于训练模型,之后入组者构成验证数据集。
- 训练集1007例(234例R0),验证集473例(122例R0);3882例入组患者中1480例有完整临床数据。
主要发现
- 简化多变量回归模型显示疾病评分(p<0.001)、分期(p=0.009)、CA125(p<0.001)、腹水(p<0.001)和分期-年龄交互项(p=0.01)预测R0。
- 验证集应用预测模型AUC为0.73(95%CI 0.67-0.78)。
- 加入疾病评分后模型性能提升至AUC 0.83(95%CI 0.79-0.88)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. METHODS: Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. RESULTS: Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p<0.001), stage (p=0.009), CA125 (p<0.001), ascites (p<0.001), and stage-age interaction (p=0.01). Applying the prediction model to the validation data resulted in an AUC of 0.73 (0.67 to 0.78, 95% CI). Inclusion of DS enhanced the model performance to an AUC of 0.83 (0.79 to 0.88, 95% CI). CONCLUSIONS: We developed and validated a prediction model for R0 that offers improved performance over previously reported models for prediction of residual disease. The performance of the prediction model suggests additional factors (i.e. imaging, molecular profiling, etc.) should be explored in the future for a more clinically actionable tool.
引用
- Horowitz NS, Larry Maxwell G, Miller A, et al. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2017. PMID: 29174555. doi:10.1016/j.ygyno.2017.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。